Denali Therapeutics Inc.
シンボルマーク: DNLI
NASDAQ
20.86
USD今日の市場価格
-14.6980
PER（株価収益率
-0.2609
PEGレシオ
2.88B
MRK キャップ
- 0.00%
DIV利回り
Denali Therapeutics Inc. (DNLI) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4623.21 | 1034.5 | 1336.2 | 865.4 | |||||||||
balance-sheet.row.short-term-investments | 4147.99 | 907.4 | 1118.2 | 571.9 | |||||||||
balance-sheet.row.net-receivables | 9.3 | 2.7 | 5 | 1.2 | |||||||||
balance-sheet.row.inventory | -6.6 | 0 | -5 | 0 | |||||||||
balance-sheet.row.other-current-assets | 130.34 | 26.9 | 36.1 | 30.6 | |||||||||
balance-sheet.row.total-current-assets | 4756.24 | 1064.1 | 1372.3 | 897.2 | |||||||||
balance-sheet.row.property-plant-equipment-net | 283.89 | 71.6 | 74.5 | 69.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 12.61 | 1.6 | 1.5 | 425.4 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 53.03 | 16.5 | 11.9 | 11.9 | |||||||||
balance-sheet.row.total-non-current-assets | 349.53 | 89.8 | 87.9 | 506.9 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.account-payables | 21.4 | 9.5 | 2.8 | 4.8 | |||||||||
balance-sheet.row.short-term-debt | 27.59 | 7.3 | 7.3 | 5.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 191.16 | 45 | 53 | 58.6 | |||||||||
Deferred Revenue Non Current | 1.05 | 0 | 0.5 | 4.7 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 270.01 | 61.2 | 63.8 | 47.7 | |||||||||
balance-sheet.row.total-non-current-liabilities | 193.36 | 45 | 53.9 | 63.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 211.49 | 45 | 60.4 | 58.6 | |||||||||
balance-sheet.row.total-liab | 802.96 | 123 | 417.8 | 441.9 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 6.81 | 1.7 | 1.7 | 1.5 | |||||||||
balance-sheet.row.retained-earnings | -4091.1 | -1116.2 | -971 | -645 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3.97 | 0.6 | -6.9 | -2.5 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 8391.07 | 2144.8 | 2018.6 | 1608.2 | |||||||||
balance-sheet.row.total-stockholders-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5105.77 | - | - | - | |||||||||
Total Investments | 4157.49 | 909 | 1118.2 | 997.4 | |||||||||
balance-sheet.row.total-debt | 218.75 | 52.2 | 60.4 | 58.6 | |||||||||
balance-sheet.row.net-debt | -256.47 | -74.9 | -157.7 | -234.9 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -145.22 | -145.2 | -326 | -290.6 | |||||||||
cash-flows.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
cash-flows.row.deferred-income-tax | -56.28 | -2.4 | 0 | 8.7 | |||||||||
cash-flows.row.stock-based-compensation | 108.1 | 108.1 | 99.8 | 85.2 | |||||||||
cash-flows.row.change-in-working-capital | -289.93 | -289.9 | -24 | -20.4 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.account-payables | 2.43 | 2.4 | 2.3 | 3.7 | |||||||||
cash-flows.row.other-working-capital | -292.36 | -292.4 | -26.3 | -24.1 | |||||||||
cash-flows.row.other-non-cash-items | 8.61 | -45.2 | -4.9 | -3 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -357.99 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.acquisitions-net | -262.25 | 0 | 123.6 | 13.1 | |||||||||
cash-flows.row.purchases-of-investments | -1813.7 | -1813.7 | -1115 | -1422.9 | |||||||||
cash-flows.row.sales-maturities-of-investments | 2075.95 | 2075.9 | 991.5 | 1409.8 | |||||||||
cash-flows.row.other-investing-activites | 262.25 | 0 | -123.6 | -13.1 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 249.31 | 249.3 | -141.4 | -21.6 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -3.1 | -3.7 | |||||||||
cash-flows.row.common-stock-issued | 17.82 | 17.8 | 296.2 | 19.3 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | 17.82 | 17.8 | 17.6 | 3.7 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 17.82 | 17.8 | 310.7 | 19.3 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -90.86 | -90.9 | -75.4 | -213.7 | |||||||||
cash-flows.row.cash-at-end-of-period | 479.87 | 127.1 | 219.5 | 295 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 570.73 | 218 | 295 | 508.6 | |||||||||
cash-flows.row.operating-cash-flow | -357.99 | -358 | -244.7 | -211.4 | |||||||||
cash-flows.row.capital-expenditure | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.free-cash-flow | -370.93 | -370.9 | -262.5 | -219.9 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 330.53 | 330.5 | 108.5 | 48.7 | |||||||||
income-statement-row.row.cost-of-revenue | 14.92 | 16.7 | 7 | 5.6 | |||||||||
income-statement-row.row.gross-profit | 315.61 | 313.8 | 101.4 | 43.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 423.88 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 103.35 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.operating-expenses | 525.05 | 510.5 | 449.2 | 344.4 | |||||||||
income-statement-row.row.cost-and-expenses | 527.23 | 527.2 | 449.2 | 344.4 | |||||||||
income-statement-row.row.interest-income | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
income-statement-row.row.ebitda-caps | -192.31 | - | - | - | |||||||||
income-statement-row.row.operating-income | -196.7 | -196.7 | -340.7 | -295.8 | |||||||||
income-statement-row.row.income-before-tax | -145.19 | -145.2 | -326 | -291.2 | |||||||||
income-statement-row.row.income-tax-expense | -12.3 | 0 | 0 | -0.6 | |||||||||
income-statement-row.row.net-income | -145.22 | -145.2 | -326 | -290.6 |
よくある質問
Denali Therapeutics Inc.DNLI 総資産とは何ですか？
Denali Therapeutics Inc. (DNLI) 総資産は 1153917000.000.
企業の年間売上高とは？
年間収益は 1267000.000である.
企業の利益率は？
利益率は 0.955 である.
企業のフリーキャッシュフローとは？
フリーキャッシュフローは -2.683.
企業の純利益率は？
純利益率は -0.439 である.
企業の総収入は？
総収入は -0.595 である.
Denali Therapeutics Inc. (DNLI) 純利益（純利益）とは何ですか？
純利益（純利益）は -145224000.000.
負債総額は？
負債合計は 52241000.000 である.
営業費用はいくらですか？
営業費用は 510504000.000 である.
会社の現金はいくらですか？
企業の現金は 127106000.000 である.